Abstract
6-Substituted fulvenes are interesting and easily accessible starting materials for the synthesis of novel-substituted titanocenes via reductive dimerisation, carbolithiation or hydridolithiation reactions, which are followed by a transmetallation reaction with titanium tetrachloride in the latter two cases. Depending on the substitution pattern, these titanocenes prove to be bioorganometallic anticancer drugs, which have significant potential against advanced or metastatic renal-cell cancer. Patients bearing these stages of kidney cancer have a poor prognosis so far and therefore real progress in the area of metal-based anticancer drugs may come from this simple and effective synthetic approach.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schilling T, Keppler BK, Heim ME, Niebch G, Dietzfelbinger H, Rastetter J, Hanauske AR (1996) Invest New Drugs 13:327–332
Melendez E (2002) Crit Rev Oncol Hematol 42:309–315
Köpf H, Köpf-Maier P (1979) Angew Chem Int Ed Engl 18:477–478
Caruso F, Rossi M (2004) Met Ions Biol Syst 42:353–384
Lummen G, Sperling H, Luboldt H, Otto T, Rubben H (1998) Cancer Chemother Pharmacol 42:415–417
Kröger N, Kleeberg UR, Mross K, Edler L, Saβ G, Hossfeld D (2000) Onkol 23:60–62
Allen OR, Croll L, Gott AL, Knox RJ, McGowan PC (2004) Organometallics 23:288–292
Causey P, Baird M (2004) Organometallics 23:4486–4494
Meyer R, Brink S, van Rensburg C, Jooné G, Görls H, Lotz S (2005) J Organomet Chem 690:117–125
Stone KJ, Little RD (1984) J Org Chem 49:1849–1853
Mosmann T (1983) J Immunol Methods 65:55–63
Strohfeldt K, Tacke M (2008) Chem Soc Rev 37:1174–1187
Sweeney NJ, Mendoza O, Müller-Bunz H, Pampillón C, Rehmann F-JK, Strohfeldt K, Tacke M (2005) J Organomet Chem 690:4537–4544
Sweeney NJ, Gallagher WM, Müller-Bunz H, Pampillón C, Strohfeldt K, Tacke M (2006) J Inorg Biochem 100:1479–1486
Erker G, Nolte R, Aul R, Wilker S, Krüger C, Noe R (1991) J Am Chem Soc 113:7594–7602
Leblanc JC, Moise C (1976) J Organomet Chem 120:65–71
Sweeney NJ, Claffey J, Müller-Bunz H, Pampillón C, Strohfeldt K, Tacke M (2007) Appl Organomet Chem 21:57–62
Strohfeldt K, Müller-Bunz H, Pampillón C, Sweeney NJ, Tacke M (2006) Eur J Inorg Chem 4621–4628
Strohfeldt K, Müller-Bunz H, Pampillón C, Sweeney NJ, Tacke M (2007) Trans Met Chem 32:971–980
Claffey J, Gleeson B, Hogan M, Müller-Bunz H, Wallis D, Tacke M (2008) Eur J Inorg Chem 4074–4082
Claffey J, Hogan M, Müller-Bunz H, Pampillón C, Tacke M (2008) ChemMedChem 3:729–731
Pampillón C, Claffey J, Strohfeldt K, Tacke M (2008) Eur J Med Chem 43:122–128
Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2007) J Organomet Chem 692:2153–2159
Pampillón C, Claffey J, Hogan M, Tacke M (2007) Z Allg Anorg Chem 633:1695–1700
Hogan M, Claffey J, Pampillón C, Tacke M (2008) Med Chem 4:91–99
Pampillón C, Claffey J, Hogan M, Strohfeldt K, Tacke M (2007) Trans Met Chem 32:434–441
Hogan M, Cotter J, Claffey J, Gleeson B, Wallis D, O’Shea D, Tacke M (2008) Helv Chim Acta 91:1787–1797
Hogan M, Claffey J, Pampillón C, Watson RWG, Tacke M (2007) Organometallics 26:2501–2506
Hickey T, Claffey J, Fitzpatrick E, Hogan M, Pampillón C, Tacke M (2007) Invest New Drugs 25:425–433
Suzuka T, Ogasawara M, Hayashi T (2002) J Org Chem 67:3355–3359
Pampillón C, Claffey J, Hogan M, Tacke M (2008) Biometals 21:197–204
Pampillón C, Sweeney N, Strohfeldt K, Tacke M (2006) Inorg Chim Acta 359:3969–3975
Pampillón C, Mendoza O, Sweeney N, Strohfeldt K, Tacke M (2006) Polyhedron 25:2101–2108
Kelter G, Sweeney NJ, Strohfeldt K, Fiebig H-H, Tacke M (2005) Anticancer Drugs 16:1091–1098
Oberschmidt O, Hanauske AR, Rehmann F-JK, Strohfeldt K, Sweeney NJ, Tacke M (2005) Anticancer Drugs 16:1071–1073
Valaderes MC, Ramos AL, Rehmann F-JK, Sweeney NJ, Strohfeldt K, Tacke M, Queiroz MLS (2006) Eur J Pharmacol 534:264–270
O’Connor K, Gill C, Tacke M, Rehmann F-JK, Strohfeldt K, Sweeney N, Fitzpatrick JM, Watson RWG (2006) Apoptosis 11:1205–1214
Oberschmidt O, Hanauske AR, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2007) Anticancer Drugs 18:317–321
Fichtner I, Pampillón C, Sweeney NJ, Strohfeldt K, Tacke M (2006) Anticancer Drugs 17:333–336
Bannon JH, Fichtner I, O’Neill A, Pampillon C, Sweeney NJ, Strohfeldt K, Watson RW, Tacke M, Mc Gee MM (2007) Br J Cancer 97:1234–1241
Dowling CM, Claffey J, Cuffe S, Fichtner I, Pampillón C, Sweeney NJ, Strohfeldt K, Watson RWG, Tacke M (2008) Lett Drug Des Discov 5:141–144
Vessières A, Plamont M-A, Cabestaing C, Claffey J, Dieckmann S, Hogan M, Müller-Bunz H, Strohfeldt K, Tacke M (2009) J Organomet Chem 694:874–877
Gunda Köllensperger, personal communication
Erxleben A, Claffey J, Tacke M (2010) J Inorg Biochem 104:390–396
Tacke M (2008) Lett Drug Des Discov 5:332–335
Beckhove P, Oberschmidt O, Hanauske AR, Pampillón C, Schirrmacher V, Sweeney NJ, Strohfeldt K, Tacke M (2007) Anticancer Drugs 18:311–315
Weber H, Claffey J, Hogan M, Pampillón C, Tacke M (2008) Toxicol In Vitro 22:531–534
Fichtner I, Claffey J, Gleeson B, Hogan M, Wallis D, Weber H, Tacke M (2008) Lett Drug Des Discov 5:489–493
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Hogan, M., Tacke, M. (2010). Titanocenes: Cytotoxic and Anti-angiogenic Chemotherapy Against Advanced Renal-Cell Cancer. In: Jaouen, G., Metzler-Nolte, N. (eds) Medicinal Organometallic Chemistry. Topics in Organometallic Chemistry, vol 32. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-13185-1_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-13185-1_5
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-13184-4
Online ISBN: 978-3-642-13185-1
eBook Packages: Chemistry and Materials ScienceChemistry and Material Science (R0)